Laura Whited, APRN
Family · Kensett, ARNPI 1447871934
Payments from drug & device makers
Across 104 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$169
- AstraZeneca$146
- Astellas Pharma US Inc$94
- Idorsia Pharmaceuticals US Inc$85
- Vanda Pharmaceuticals Inc.$80
- plus $344 from 14 others
What the payments were for
- Food & beverage$1,96795%
- Education$945%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $1,143 |
| GSK | 10 | $169 |
| AstraZeneca | 7 | $146 |
| Astellas Pharma US Inc | 1 | $94 |
| Idorsia Pharmaceuticals US Inc | 3 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $80 |
| Lundbeck LLC | 3 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Insulet Corporation | 1 | $26 |
| Verona Pharma, Inc. | 1 | $23 |
| Viatris Specialty LLC | 1 | $23 |
| Indivior Inc. | 1 | $22 |
| Braeburn Inc. | 1 | $20 |
| Alkermes, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Organon | 1 | $9 |
How this compares
$2,061 in reported general payments places this provider in the 80th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 134 | $104,432 |
| OzempicSemaglutide | 76 | $86,323 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $81,697 |
| EliquisApixaban | 65 | $47,393 |
| Spiriva HandihalerTiotropium Bromide | 35 | $20,029 |
| Nurtec OdtRimegepant Sulfate | 14 | $19,306 |
| MounjaroTirzepatide | 16 | $18,982 |
| JanuviaSitagliptin Phosphate | 24 | $18,651 |
| FarxigaDapagliflozin Propanediol | 14 | $18,502 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $17,854 |
| Bydureon BciseExenatide Microspheres | 21 | $16,553 |
| SymbicortBudesonide/Formoterol Fumarate | 57 | $13,145 |
| Xigduo XrDapaglifloz Propaned/Metformin | 23 | $12,937 |
| EntrestoSacubitril/Valsartan | 13 | $11,309 |
| MyrbetriqMirabegron | 20 | $10,404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta | $169 | $97,244164 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $146 | $49,50299 claims |
| Lilly USA, LLCMounjaro | $13 | $18,98216 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $10,40420 claims |
| AbbVieLinzess | $1,143 | $9,11315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,103 family providers in Arkansas.
Other family in Kensett
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.